Thanks for the info profit taker re South Cross Equities and your call to Biosignal. That the lenses poor performance due to protein deposition is “Not a major issue” is good to hear. They have probably been aware of the problem for the last month. Let’s hope they find a solution soon.
The report was mixed news. On one hand, the oil pipe corrosion bench trial has been delayed from 24 May 06 statement of ‘being completed at the beginning of Q4 2006’. It will now be completed in 2007. On the other hand the continuing success with their therapeutics (cystic fibrosis and urinary tract infection treatments) is exciting indeed.
So far I feel bos is making steady progress.
BOS Price at posting:
0.0¢ Sentiment: Buy Disclosure: Not Held
